Peter Verheesen

5PUBLICATIONS
35CO-AUTHORS
AllergySeparation technologiesApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Sep 11, 2026
Efficacy and safety of subcutaneous efgartigimod with prednisone in moderate-to-severe pemphigus (ADDRESS): a global, phase III, randomised controlled, double-blind trial.

|Nov 06, 2023
Bullous pemphigoid induced by IgG targeting type XVII collagen non-NC16A/NC15A extracellular domains is driven by Fc gamma receptor- and complement-mediated effector mechanisms and is ameliorated by neonatal Fc receptor blockade.

Manuela Pigors, Sabrina Patzelt, Niklas Reichhelm

|May 28, 2022
Correction: Zakrzewicz et al. Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus? Cells 2022, 11, 942.

Anna Zakrzewicz, Celina Würth, Benedikt Beckert

|Mar 25, 2022
Stabilization of Keratinocyte Monolayer Integrity in the Presence of Anti-Desmoglein-3 Antibodies through FcRn Blockade with Efgartigimod: Novel Treatment Paradigm for Pemphigus?

Anna Zakrzewicz, Celina Würth, Benedikt Beckert

|Nov 14, 2020
Glycine 236 in the Lower Hinge Region of Human IgG1 Differentiates FcγR from Complement Effector Function.

Maximilian Brinkhaus, Ruben G J Douwes, Arthur E H Bentlage

Pageof 1

Frequent Collaborators

2 joint publications

Ritva Tikkanen

1 joint publications

Arthur E H Bentlage

1 joint publications

A Robin Temming

1 joint publications

Steven W de Taeye